Form 4 for AEON AEON Biopharma, Inc.
Accepted 2026-02-19 00:00:00 ET · period of report 2026-02-17 · accession 0001104659-26-017726 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-02-19 | 2026-02-17 | AEON | Bancroft Robert E. | Pres, CEO, Dir | A - Grant | $0.00 | +3.00M | 3.18M | +1,694% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-02-17 | A | A | 3,000,000 | $0.00 | 3,177,103 | D | — | — | (F1) Represents an award of restricted stock units granted on February 17, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date. |